Zilxi - (1.50% ; Topical Aerosol Foam)

Generic Name	Minocycline Hydrochloride	Innovator	Journey medical corp
Dosage	1.50% ; Topical Aerosol Foam	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	Zilxi is a tetracycline-class drug indicated for the treatment of inflammatory lesions of rosacea in adults.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*******	*** / *********	*** **, ****	*******	****	** ***** *, ****

Chronology Of Events